We would like to thank Murat Yuksel et al. [1] for their comments on our article [2] . They have asked if we consider that the elevated levels of mean platelet volume (MPV) and total white blood cell (WBC) count predict cardiovascular events in acute coronary syndrome (ACS) patients; therefore the WBC/MPV ratio (WMR) values may not be considered a good prognostication marker due to dividing WBC by MPV. Although they offered some comments regarding the association of inflammatory markers with ACS, they should focus more on MPV and total WBC count in non-ST elevation ACS (NSTE-ACS) instead of platelet and lymphocyte counts. Given their notions and those mentioned in our article, we propose some points in this letter.
The prognostic role of MPV has been demonstrated among patients with myocardial infarction (MI) [3] , however, findings in terms of MPV have not been consistent among NSTE-ACS or NSTEMI. Tekbas et al. [4] have shown that elevated MPV increased the risk of mortality in ST elevation MI (STEMI) during hospitalization, but not in NSTEMI group. Taglieri et al. [5] have also demonstrated that, among NSTE-ACS patients, elevated MPV group was at higher risk for combined cardiovascular death and MI, while the association with each of the endpoints alone has decreased. Furthermore, in another prospective study, MPV was not associated with 6-month adverse events in NSTE-ACS patients [6] . One reason for this issue can be explained by findings of Rinder et al. [7] , who have found that the interaction between platelets and leukocytes at culprit lesion of atherosclerotic plaques, leading to inflammatory pathways and subsequent atherothrombosis, is a dynamic process attributable to platelet activation status and leukocyte adhesion ability. Thus, it is likely that in the progression of NSTE-ACS, both activated and inactivated platelets are involved, which may be suggestive of the fact why increased MPV is not associated with adverse events in NSTE-ACS. Beside the MPV values, the majority of studies have shown that higher total WBC count has been a prognostic marker for patients at greater risk for developing cardiovascular adverse events at follow-up duration in ACS patients [8] , MI alone [9] , or NSTE-ACS [10] .
Taking into account these findings and the prognostic role of WMR as a novel inflammationbased marker reflecting both MPV and WBC count effects in ACS, it seems more likely to consider that the WMR may not be useful in STEMI patients due to a vast amount of studies showing association between elevated MPV and STEMI prognosis. On the other hand, the prognostic ability of WMR in predicting patients at greater risk for worse outcomes in NSTE-ACS may be of great importance because of lack of association between elevated MPV and outcomes of such patients. Further large-scaled prospective study may be useful in elucidating the importance of WMR in the risk stratification and treatment modalities of NSTE-ACS patients.
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